Published in PLoS One on April 09, 2012
Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000. Clin Vaccine Immunol (2014) 0.78
Attenuation of monkeypox virus by deletion of genomic regions. Virology (2014) 0.76
Comparison of Monkeypox Virus Clade Kinetics and Pathology within the Prairie Dog Animal Model Using a Serial Sacrifice Study Design. Biomed Res Int (2015) 0.75
Complement Evasion Strategies of Viruses: An Overview. Front Microbiol (2017) 0.75
The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med (2004) 6.32
Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol (1988) 4.92
Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques (1997) 3.74
Vaccinia virus replication. I. Requirement for the host-cell nucleus. J Virol (1979) 3.10
Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc Natl Acad Sci U S A (2002) 2.95
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A (2010) 2.69
Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature (1988) 2.63
Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science (1990) 2.49
Monkeypox transmission and pathogenesis in prairie dogs. Emerg Infect Dis (2004) 2.45
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology (2005) 2.36
A tale of two clades: monkeypox viruses. J Gen Virol (2005) 2.24
Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci U S A (1992) 2.12
Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med (2006) 2.11
Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg (2005) 1.91
Detection of monkeypox virus with real-time PCR assays. J Clin Virol (2006) 1.77
A dominant selectable marker for the construction of recombinant poxviruses. Gene (1988) 1.72
Monkeypox zoonotic associations: insights from laboratory evaluation of animals associated with the multi-state US outbreak. Am J Trop Med Hyg (2007) 1.67
Isolation of cowpox virus A-type inclusions and characterization of their major protein component. Virology (1986) 1.57
Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol (2008) 1.49
A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. J Gen Virol (2009) 1.49
Regulation of complement activity by vaccinia virus complement-control protein. J Infect Dis (1992) 1.49
Human monkeypox: clinical features of 282 patients. J Infect Dis (1987) 1.44
Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J Immunol (2006) 1.21
The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J Exp Med (2008) 1.19
The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein. Virology (1997) 1.17
Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins. J Immunol (2005) 1.15
Dosage comparison of Congo Basin and West African strains of monkeypox virus using a prairie dog animal model of systemic orthopoxvirus disease. Virology (2010) 1.12
Viral mimicry of the complement system. J Biosci (2003) 1.08
Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP). Mol Immunol (1999) 1.08
Surviving mousepox infection requires the complement system. PLoS Pathog (2008) 1.07
Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J Immunol (2009) 1.03
Kinetic analysis of the interactions between vaccinia virus complement control protein and human complement proteins C3b and C4b. J Virol (2004) 1.00
Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol Res (2006) 0.99
Identification of complement regulatory domains in vaccinia virus complement control protein. J Virol (2005) 0.98
Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein. J Virol (2003) 0.97
Herpes and pox viral complement control proteins: 'the mask of self'. Trends Immunol (2003) 0.94
Smallpox inhibitor of complement enzymes (SPICE): regulation of complement activation on cells and mechanism of its cellular attachment. J Immunol (2008) 0.92
Synthesis of mRNA guanylyltransferase and mRNA methyltransferases in cells infected with vaccinia virus. J Virol (1977) 0.91
The Vaccinia virus complement control protein modulates adaptive immune responses during infection. J Virol (2010) 0.88
Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection. J Virol (2011) 0.85
A-type inclusion bodies: a factor influencing cowpox virus lesion pathogenesis. Arch Virol (2011) 0.83
Poxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein. J Virol (2010) 0.83
The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med (2004) 6.32
Estimating the future number of cases in the Ebola epidemic--Liberia and Sierra Leone, 2014-2015. MMWR Surveill Summ (2014) 4.53
A computational genomics pipeline for prokaryotic sequencing projects. Bioinformatics (2010) 2.63
Monkeypox transmission and pathogenesis in prairie dogs. Emerg Infect Dis (2004) 2.45
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology (2005) 2.36
A tale of two clades: monkeypox viruses. J Gen Virol (2005) 2.24
Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics (2007) 2.10
p27 binds cyclin-CDK complexes through a sequential mechanism involving binding-induced protein folding. Nat Struct Mol Biol (2004) 2.07
Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis (2008) 2.00
Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg (2005) 1.91
Genome sequence diversity and clues to the evolution of variola (smallpox) virus. Science (2006) 1.84
On the origin of smallpox: correlating variola phylogenics with historical smallpox records. Proc Natl Acad Sci U S A (2007) 1.84
Detection of monkeypox virus with real-time PCR assays. J Clin Virol (2006) 1.77
Real-time PCR system for detection of orthopoxviruses and simultaneous identification of smallpox virus. J Clin Microbiol (2004) 1.74
Clinical manifestations of human monkeypox influenced by route of infection. J Infect Dis (2006) 1.71
Monkeypox zoonotic associations: insights from laboratory evaluation of animals associated with the multi-state US outbreak. Am J Trop Med Hyg (2007) 1.67
Brazilian vaccinia viruses and their origins. Emerg Infect Dis (2007) 1.64
characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak. Clin Diagn Lab Immunol (2005) 1.62
Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology (2004) 1.58
Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis (2005) 1.54
Monkeypox or varicella? Lessons from a rash outbreak investigation in the Republic of the Congo. Am J Trop Med Hyg (2009) 1.54
Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother (2009) 1.52
Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest (2005) 1.50
A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. J Gen Virol (2009) 1.49
The envelope G3L protein is essential for entry of vaccinia virus into host cells. J Virol (2006) 1.49
Effects of a dental adhesive incorporating antibacterial monomer on the growth, adherence and membrane integrity of Streptococcus mutans. J Dent (2009) 1.46
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol (2005) 1.44
A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine (2006) 1.43
Ecological niche and geographic distribution of human monkeypox in Africa. PLoS One (2007) 1.41
National surveillance for human and pet contact with oral rabies vaccine baits, 2001-2009. J Am Vet Med Assoc (2012) 1.39
Chasing Jenner's vaccine: revisiting cowpox virus classification. PLoS One (2011) 1.33
Real-time PCR assay to detect smallpox virus. J Clin Microbiol (2003) 1.32
Pharmacists and harm reduction: A review of current practices and attitudes. Can Pharm J (Ott) (2012) 1.30
Human monkeypox infection: a family cluster in the midwestern United States. J Infect Dis (2004) 1.26
Evaluation of smallpox vaccines using variola neutralization. J Gen Virol (2009) 1.21
Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees. Microbes Infect (2005) 1.20
Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol (2007) 1.20
In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob Agents Chemother (2008) 1.19
Outbreaks of human monkeypox after cessation of smallpox vaccination. Trends Microbiol (2012) 1.17
GC content-based pan-pox universal PCR assays for poxvirus detection. J Clin Microbiol (2009) 1.15
Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins. J Immunol (2005) 1.15
A silent enzootic of an orthopoxvirus in Ghana, West Africa: evidence for multi-species involvement in the absence of widespread human disease. Am J Trop Med Hyg (2010) 1.13
Discovery of monkeypox in Sudan. N Engl J Med (2006) 1.13
Upregulation of retinal dehydrogenase 2 in alternatively activated macrophages during retinoid-dependent type-2 immunity to helminth infection in mice. PLoS Pathog (2012) 1.13
Dosage comparison of Congo Basin and West African strains of monkeypox virus using a prairie dog animal model of systemic orthopoxvirus disease. Virology (2010) 1.12
The phylogenetics and ecology of the orthopoxviruses endemic to North America. PLoS One (2009) 1.12
Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. J Biol Chem (2004) 1.11
Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3. Vaccine (2007) 1.11
The Merits of Malaria Diagnostics during an Ebola Virus Disease Outbreak. Emerg Infect Dis (2016) 1.08
Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine (2006) 1.08
ORF virus infection in children: clinical characteristics, transmission, diagnostic methods, and future therapeutics. Pediatr Infect Dis J (2007) 1.08
Monkeypox virus and insights into its immunomodulatory proteins. Immunol Rev (2008) 1.07
Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity. Mol Ther (2011) 1.06
Spectrum of infection and risk factors for human monkeypox, United States, 2003. Emerg Infect Dis (2007) 1.05
Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus. J Virol (2011) 1.05
A role for the host coatomer and KDEL receptor in early vaccinia biogenesis. Proc Natl Acad Sci U S A (2008) 1.05
Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. J Virol (2010) 1.02
Real-time PCR assay to identify variants of Vaccinia virus: implications for the diagnosis of bovine vaccinia in Brazil. J Virol Methods (2008) 1.01
The identification and characterization of a monoclonal antibody to the vaccinia virus E3 protein. Virus Res (2007) 0.99
A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine (2010) 0.98
Monkeypox outbreak diagnostics and implications for vaccine protective effect. Nat Med (2006) 0.98
Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack. J Virol (2008) 0.97
Eczema vaccinatum resulting from the transmission of vaccinia virus from a smallpox vaccinee: an investigation of potential fomites in the home environment. Vaccine (2008) 0.97
A rapid, high-throughput vaccinia virus neutralization assay for testing smallpox vaccine efficacy based on detection of green fluorescent protein. J Virol Methods (2008) 0.97
Effects of georeferencing effort on mapping monkeypox case distributions and transmission risk. Int J Health Geogr (2012) 0.96
Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg Infect Dis (2006) 0.96
Real-time PCR assays for the specific detection of monkeypox virus West African and Congo Basin strain DNA. J Virol Methods (2010) 0.96
Prevalence of antibodies against orthopoxviruses among residents of Likouala region, Republic of Congo: evidence for monkeypox virus exposure. Am J Trop Med Hyg (2007) 0.96
Comparison of West African and Congo Basin monkeypox viruses in BALB/c and C57BL/6 mice. PLoS One (2010) 0.96